Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magtrace for Delayed SLNB in DCIS
NCT06868238Phase 2Suspended
- Sponsor
- University of Florida
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Magtrace in ductal carcinoma in situ (DCIS), sponsored by University of Florida. Primary endpoint: Percentage of patients with DCIS who do not undergo sentinel lymph node biopsy. Started Oct 2026; status: suspended.
02
Drugs
Magtrace
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT06868238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868238.